Contributors Participating in Society

Social Participation Priorities

PharmaEssentia focuses on the research, development, and application of MPN drugs; supports MPN care and global healthcare empowerment; and monitors international and local health and social issues. PharmaEssentia’s three main social participation priorities include accessibility, affordability and availability of medicines; patient care and global healthcare empowerment; and public welfare. We participate in domestic and overseas seminars, medical education initiatives, and patient experience-sharing activities, and have long supported patient, social welfare, and arts and culture education organizations as we work to strengthen our presence across multiple regions as a provider of medical education, patient support, and charitable care. We hope to benefit more patients, healthcare professionals, and communities in future through cross-disciplinary collaborations and localized initiatives that enable our professional capabilities to generate broader positive impacts.

Compassionate treatment achievements over the past five years

Focus on Patient Needs and Provide Comprehensive Support

• PharmaEssentia Taiwan: Patient Support Program

  In 2025, PharmaEssentia and the Taiwan Myeloproliferative Neoplasms Association (TMPNA) jointly hosted the World MPN Day Third TMPNA Member Conference, helping patients understand and access MPN resources through keynote presentations and face-to-face discussions with experts. TMPNA was founded in 2021 and has 94 members as of 2025. We hope to expand community networks for MPN patients and their families through related collaborations and promotions.

• Panco: MPN iCare

  Panco established the MPN iCare patient health education interactive platform to provide health education to patients and their families. To help physicians better understand MPN and the efficacy of long-acting interferon therapy, we hosted 28 seminars for healthcare professionals and patients in 2025. These events helped participants better understand MPN and treatment options. Patients and family members can engage in online interactions at any time through the health education section of the platform and the official LINE account.

• PharmaEssentia USA: Patient Support SOURCE Program

  This program is open to current BESREMi® prescription holders, and provides comprehensive support encompassing insurance information, self-pay discount programs, medication guidance, and prescription renewal processes, enhancing convenience for patients who are unable to use our medications due to delayed insurance payments or insufficient insurance coverage. The program also provides medication to uninsured or underinsured patients. Our goal is to ensure a stable supply of PharmaEssentia medications to patients and reduce their financial burdens.

• PharmaEssentia Japan: Patient Support Program

  PharmaEssentia Japan strengthened its commitment to Japanese patients in 2025 through the “PV Navigator” website, which provides disease education, diagnostic support tools, and information on insurance benefits to help patients reduce financial treatment burdens. PharmaEssentia Japan also operates the “Towards Tomorrow” member platform, which offers a personalized patient support ecosystem. The platform provides consultations on medical fees and operates a patient support hotline that addresses disease and treatment questions; medication guidance is provided by professional nurses.
  PharmaEssentia Japan also implemented multiple measures to enhance healthcare accessibility, including medication home delivery services, free consultations on medical fees, and patient support call centers, which reduced patient burdens, improved treatment accessibility, and responded to patient care needs. In 2025, 54 patients and their families in Japan used these services.

Reasonable Evidence-Based Pricing

PharmaEssentia has long been committed to supporting underserved populations and advancing healthcare programs in developing countries, with the aim of improving access to medicines by ensuring that healthcare resources are not limited by geographic, economic, or social conditions. According to the World Health Organization, patients with rare diseases account for approximately 0.65% to 1% of the world’s total population, and most suffer from genetic diseases. Due to the small number of patients and dispersed demand, patients with rare diseases often occupy a vulnerable position within the healthcare system. Among them, elderly patients with rare diseases frequently face both economic and medical challenges, making them the “most vulnerable among the vulnerable.” BESREMi® leverages innovative technology to address the needs of these underserved groups, offering enhanced safety, longer-lasting efficacy, and greater suitability for older adults.

PharmaEssentia remains committed to the development of innovative orphan drug technologies while improving access to quality healthcare for underserved populations around the world.

PharmaEssentia is committed to improving access to innovative medicines for patients with unmet medical needs. The Company has established the following objectives:

1. Expand global access to BESREMi® (Ropeginterferon alfa-2b) through accelerated regulatory approvals and commercialization.
2. Advance clinical development programs and broaden therapeutic applications, including PV, ET, PMF and other hematological and immune-related diseases.
3. Continue compassionate use programs and support patient access before product commercialization.
4. Improve affordability through responsible pricing strategies and cost-effectiveness assessments.
5. Increase patient access through reimbursement coverage, patient support programs, and collaboration with healthcare stakeholders.

During 2025, PharmaEssentia achieved the following outcomes related to healthcare products and medicines:

1. BESREMi® obtained PV marketing approvals in Hong Kong, Brazil and Argentina, bringing cumulative approvals to more than 50 countries worldwide.
2. The Company continued expanding access through licensing and commercialization partnerships across Latin America, the Middle East and South Asia.
3. Korea obtained conditional national reimbursement coverage for BESREMi®, improving affordability and access for patients.
4. A total of 59 patients benefited from compassionate use programs during 2025.
5. Global cumulative clinical trial participation reached 1,316 patients.
6. Patient support and disease education programs continued in Taiwan, Japan and the United States to enhance treatment adherence and disease awareness.

Enhancing Access to Medicines through Medicines Innovation and Compassionate Use Programs

PharmaEssentia has successfully optimized conventional therapies through the development of Ropeginterferon alfa-2b (Ropeg), a next-generation pegylated long-acting interferon. Featuring a multi-indication potential, Ropeg overcomes many of the limitations associated with conventional interferon therapies in terms of administration and treatment outcomes. Ropeg is the first long-acting interferon approved by the U.S. FDA for the treatment of polycythemia vera (PV) across all patient risk categories and has received orphan drug designation as well as inclusion in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines. Its extended duration of action reduces dosing frequency and treatment burden, helping improve patient convenience and long-term treatment adherence.

In addition, PharmaEssentia enhances access to medicines through its Compassionate treatment, which prioritize patients with severe medical conditions, economically disadvantaged populations, and elderly patients. These programs help bridge the gap between clinical need and product availability by providing earlier access to innovative therapies before commercial launch, thereby further improving access to treatment.

Medical products donations based on WHO Guidelines for medicine donations

PharmaEssentia supports patient access through compassionate use programs and medicine donation initiatives for patients who have unmet medical needs and are unable to obtain treatment through normal commercial channels. The Company continues to provide medicines through compassionate use programs prior to product commercialization and regulatory approval where permitted by applicable laws and regulations.

In 2025, 59 patients benefited from these programs. Medicine donations are managed under applicable regulatory requirements, medical oversight and patient eligibility criteria to ensure appropriate use, patient safety, product quality and equitable access.

Patient Assistance and Reimbursement

PharmaEssentia proactively works to obtain national insurance reimbursement inclusion in countries where our products have secured marketing authorization to reduce patient burdens. At present, we have successfully secured national insurance reimbursement inclusion in Taiwan, Korea, and Japan, as well as conditional social reimbursement in Korea and Brazil.

Ensuring Diversity in Clinical Trial Participation

PharmaEssentia publicly discloses clinical trial results across different patient populations and age groups. The Company considers participant diversity when designing and conducting clinical trials and provides appropriate support measures based on participants’ specific needs and characteristics to facilitate trial participation.

PharmaEssentia recognizes the importance of accessibility and transparency in clinical research. While safeguarding patient privacy, complying with applicable regulatory requirements, and maintaining research integrity, the Company is committed to disclosing and sharing clinical research-related information to support healthcare professionals, researchers, and other stakeholders in accessing scientifically valuable research findings, thereby contributing to continued advancement in healthcare.

PharmaEssentia enhances the accessibility of clinical research information through publications, medical conferences, academic journals, and relevant data request mechanisms. Publicly available research findings cover pre- and post-approval clinical studies, real-world data analyses, cost-effectiveness analyses, and pharmacoeconomic and health economics data. PharmaEssentia continues to share scientific evidence with the medical and academic communities, thereby improving the accessibility and practical value of research findings.

With regard to the demographic breakdown of clinical research participants, publicly available research findings also include analyses of subjects across different populations and age groups, including pharmacokinetic, pharmacodynamic, efficacy, and safety analyses by race and age group. Such information helps healthcare professionals better understand clinical outcomes across different participant populations and supports more inclusive and evidence-based clinical practice.

The Company strengthens its commitment to clinical research transparency in accordance with the PhRMA/EFPIA Principles for Responsible Clinical Trial Data Sharing. Since 2009, the Company has established a data request and sharing process for approved Phase I–IV clinical trials. This mechanism allows external researchers, upon signing a Confidentiality Agreement and receiving approval, to request access to the following: study protocols, anonymized patient-level data, statistical analysis datasets, and Clinical Study Reports (CSRs).

The Company also actively disseminates research and development findings to the medical community through presentations at national and international scientific and medical conferences, as well as publications in academic journals.

✽ Data requests may be declined where disclosure may present a risk of patient re-identification, where sharing is restricted by applicable laws, local regulatory requirements, contractual obligations, or data licensing conditions, or where studies remain subject to ongoing regulatory review or publication processes.

By sharing clinical research data in a manner that protects patient privacy, complies with applicable regulations, and upholds principles of research integrity, PharmaEssentia contributes to the advancement of public health and supports the continued development of biomedical science.

• Center for Drug Evaluation, Foundation for Medicinal Product Evaluation

PharmaEssentia remains committed to the development of innovative orphan drug technologies while improving access to quality healthcare for underserved populations around the world.

PharmaEssentia is committed to improving access to innovative medicines for patients with unmet medical needs. The Company has established the following objectives:

1. Expand global access to BESREMi® (Ropeginterferon alfa-2b) through accelerated regulatory approvals and commercialization.
2. Advance clinical development programs and broaden therapeutic applications, including PV, ET, PMF and other hematological and immune-related diseases.
3. Continue compassionate use programs and support patient access before product commercialization.
4. Improve affordability through responsible pricing strategies and cost-effectiveness assessments.
5. Increase patient access through reimbursement coverage, patient support programs, and collaboration with healthcare stakeholders.

During 2025, PharmaEssentia achieved the following outcomes related to healthcare products and medicines:

1. BESREMi® obtained PV marketing approvals in Hong Kong, Brazil and Argentina, bringing cumulative approvals to more than 50 countries worldwide.
2. The Company continued expanding access through licensing and commercialization partnerships across Latin America, the Middle East and South Asia.
3. Korea obtained conditional national reimbursement coverage for BESREMi®, improving affordability and access for patients.
4. A total of 59 patients benefited from compassionate use programs during 2025.
5. Global cumulative clinical trial participation reached 1,316 patients.
6. Patient support and disease education programs continued in Taiwan, Japan and the United States to enhance treatment adherence and disease awareness.

Enhancing Access to Medicines through Medicines Innovation and Compassionate Use Programs

PharmaEssentia has successfully optimized conventional therapies through the development of Ropeginterferon alfa-2b (Ropeg), a next-generation pegylated long-acting interferon. Featuring a multi-indication potential, Ropeg overcomes many of the limitations associated with conventional interferon therapies in terms of administration and treatment outcomes. Ropeg is the first long-acting interferon approved by the U.S. FDA for the treatment of polycythemia vera (PV) across all patient risk categories and has received orphan drug designation as well as inclusion in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines. Its extended duration of action reduces dosing frequency and treatment burden, helping improve patient convenience and long-term treatment adherence.
In addition, PharmaEssentia enhances access to medicines through its Compassionate treatment, which prioritize patients with severe medical conditions, economically disadvantaged populations, and elderly patients. These programs help bridge the gap between clinical need and product availability by providing earlier access to innovative therapies before commercial launch, thereby further improving access to treatment.

Patient Assistance and Reimbursement

PharmaEssentia proactively works to obtain national insurance reimbursement inclusion in countries where our products have secured marketing authorization to reduce patient burdens. At present, we have successfully secured national insurance reimbursement inclusion in Taiwan, Korea, and Japan, as well as conditional social reimbursement in Korea and Brazil.

Ensuring Diversity in Clinical Trial Participation

PharmaEssentia publicly discloses clinical trial results across different patient populations and age groups. The Company considers participant diversity when designing and conducting clinical trials and provides appropriate support measures based on participants’ specific needs and characteristics to facilitate trial participation.

Local Capacity Building in Developing Countries – China as an Example

PharmaEssentia focuses on developing countries identified by the Access to Medicine Index (ATMI) and is committed to supporting the development of local healthcare systems. By strengthening local healthcare system capacity and promoting education for healthcare providers and patients, the Company aims to improve public access to essential medicines. The China market is used below as an example to illustrate the relevant initiatives.

Initiative 1: Collaborating with local patient organizations to promote patient and healthcare professional education and enhance rare disease care capacity

• Community support:

  PharmaEssentia collaborates with patient organizations in China to regularly publish educational articles on patients’ social media platforms and invite disease-area experts to provide ongoing patient education through activities such as online sessions and offline free clinics.

• Patient education:

  Through systematic patient education (e.g., guidance on medication intervals, management of common side effects, and monitoring instructions), patients are supported in recognizing early symptoms and encouraged to seek timely treatment, thereby reducing the risk of severe complications and hospitalization costs. In addition, patient education enhances PV patients’ self-management and treatment adherence, which in turn strengthens the real-world reputation of Ropeginterferon and expands its market penetration in China, further increasing the willingness of hospitals and the national basic medical insurance system to adopt the therapy.

• Provider education:

  PharmaEssentia organized a symposium in Beijing, China, to support physicians in mastering key aspects of Ropeginterferon therapy, including dose adjustment, biomarker monitoring, and side-effect management, thereby facilitating the integration of the new drug into routine clinical practice and supporting the education of standardized treatment pathways. Given that treatment strategies and clinical decisions may vary across specialties, the symposium provided healthcare professionals with a unified and efficient understanding of symptom management and comorbidity care across the early, middle, and advanced stages of disease. This initiative also promotes cross-hospital, cross-regional, and cross-disciplinary collaboration in clinical practice.

Implementation Frequency

• Patient Education Meetings : Once to twice per month
• Educational Articles on TongXinJiaYuan Platform: published 10 patient education science articles and 6 educational videos, generating a total of 27,501 views.
• CSCO Hematology & Oncology Symposium：Once a year
• CASH China Hematology Development Conference:：Once a year
• Sponsored participation in approximately 16 academic conferences across China.
• Regularly organized departmental meetings and expert participation in relevant meetings.

Initiative 2: Collaborating with Local Hematology Hospitals to Strengthen Clinical Research and Disease Care Capacity

• R&D: PharmaEssentia’s Beijing subsidiary has established partnerships with 20 hospitals in China that specialize in hematology. Building on this local healthcare network, the Company continues to advance multiple clinical studies related to hematologic diseases, including the HOPE-PMF study, the PV extension study, and the ET extension study.

• The steady advancement of these clinical studies helps deepen PharmaEssentia’s long-term partnerships with local healthcare institutions and strengthen the local healthcare system’s capacity in rare hematologic disease research, clinical trial management, and patient care. At the same time, these R&D collaborations lay the foundation for future product launches, clinical adoption, and market promotion, further supporting the China market in introducing innovative therapies and enhancing disease care capacity.

Initiative 3: Pharmacovigilance-Continuously monitoring and reporting drug safety information to safeguard patient rights and well-being.

In 2025, PharmaEssentia’s Beijing subsidiary in China established and implemented a comprehensive Pharmacovigilance (PV) program, covering areas such as training systems, continuous monitoring, and process review. This initiative enhances patient safety, ensures regulatory compliance, and strengthens market trust. PV training and SOP procedures support the timely provision of complete and consistent safety data and supporting documentation, thereby improving the transparency and credibility of safety monitoring data and further enhancing the confidence of healthcare professionals and patients in the Company’s products.

Implementation Frequency

• Provide timely training for new employees.
• Conduct annual training sessions for all employees.
• Supplier Management: In 2025, the PV CRO (Pharmaron) report-handling team and call center team will circulate weekly/monthly project updates and submission status. Literature research is conducted biweekly.
• Review PV SOPs once every two years.

Initiative 4: Supply Chain Management: Strengthening cross-regional collaboration to establish a global standardized supply chain system, leveraging global experience to inform the China market and deepen local competitive advantages.

PharmaEssentia centers its supply chain and Pharmacovigilance (PV) management system on compliance with regulatory requirements and guidelines across different jurisdictions, aiming to establish a standardized model that enables synchronized operations across multiple countries. This model encompasses end-to-end temperature-controlled monitoring, execution of global SOPs, and cross-border training mechanisms to ensure consistent product quality and safety under diverse regulatory environments. The global supply chain management framework covers not only major markets such as the United States, but also extends to developing countries, combining centralized and localized supply models to flexibly allocate resources across markets. Cold-chain logistics are adopted to guarantee safe and stable drug transportation. The standardized global supply chain and PV mechanisms also serve as a valuable reference for the China market, ensuring alignment of local supply chain and safety monitoring standards with global practices, thereby enhancing compliance efficiency and strengthening clinical trust in China.

Older adults actively participated in courses covering strength and aerobic exercises, Zumba, towel exercises, and dementia prevention

Feedback from participants:

• Taitung Second Dementia Care Building: The courses aligned well with the needs of older adults with cataracts, and the instructors were engaging and professional.
• Taimali Dawang Site: Participants found the dietary health information (such as the information on green lattes) to be novel, practical, and beneficial for gastrointestinal health.
• Donghe Taiyuan Site: The participants thanked the instructor for showing them stretching exercises which relieved lower back pain and discomfort, as these were very helpful for older adults with mobility difficulties.

Feedback from teachers: We thank PharmaEssentia for their support and for organizing the Biodiversity Surprise Box course, which helped the students learn through observation, discussion, and hands-on crafting of shadow puppets. Student feedback:

“This course gave me a better understanding of animals and plans, and I also learned how to create a unique shadow puppet show that I performed in front of other students.”
“I was most interested in drawing the butterflies and cutting out their wings. Although it was difficult, I learned a lot and hope to take this course again.”